Resources

In the past 3 weeks we added the following 483s to our database of 11,000+ FDA inspection documents. You can obtain 483s, EIRs, InspectorProfiles, and more at the FDAzilla store. Sign up for your risk-free trial of the leading GMP intelligence newsletter. [supsystic-tables id=14] Like This & Want More? Sign up to get free […]

This is a particularly spare week for warning letter publication. There is only 1 to an API manufacturer, and we cover it below. DRUGS: Henan Lihua Pharmaceutical Co. Ltd (China) received a warning letter on June 21st, 2018 based on the outcome of an inspection ending December 14th, 2017. The firm manufactures APIs and was […]

Laws, Regulations, Guidance, and Concept Papers: Guidance documents this week were from the FDA, EMA, and HPRA.Among the FDA ones are 2 programs where FDA will further pursue and investigate criteria for their Quality metrics program.The non-guidance documents include publications from MHRA, EMA, FDA, TGAA, and ICH. Several are worth a serious read. Enforcement: By […]

Today I’d like to show you how to do supplier monitoring and benchmarking using FDAzilla Enforcement Analytics. We’ll start with a simple example of API manufacturers located outside of the United States. [NOTE: Don’t have access to FDAzilla Enforcement Analytics? Get your personalized CMO/Supplier Assessment using the techniques discussed in this article here.] Supplier Monitoring […]

FDA posted 15 warning letters this week — many issued by the Center for Tobacco Products, and 3 issued for firms in the areas we cover. GLP STUDIES, BIMO: Benedict S. Kiao, MD, at the Oeyama-Moto Medical Group Foundation, Inc (West Covina, CA) received a warning letter dated May 21st, 2018, based on the outcome […]

Laws, Regulations, Guidance, and Concept Papers: Lots of PIC/S guidance this week along with a couple from the FDA and EMA and 1 each from MHRA and HPRA.FDA’s withdrawal of a draft biosimilar guidance is in response to industry concerns about the bar that was set in establishing biosimilarity over time. It will be interesting […]

A slow warning letter week, 3 from the Center for Tobacco Products and 1 issued to a pharma manufacturer that we address below: Taiwan Biotech Company Ltd (Taiwan R.O.C.) received a warning letter dated May 31st, 2018 based on the outcome of an inspection ending on September 11th, 2017. The firm manufactures over-the-counter drug products. […]

Laws, Regulations, Guidance, and Concept Papers A busy week on the guidance publication front for FDA, WHO, HPRA, and Health Canada. A busy weekend of reading material! Among the most important from the FDA is the 21-page item on alternative mechanisms for complying with the GMPs for combination products.The non-guidance area includes the usual collection […]

In the past 2 weeks we added the following 483s to our database of 11,000+ FDA inspection documents. You can obtain 483s, EIRs, InspectorProfiles, and more at the FDAzilla store. Sign up for your risk-free trial of the leading GMP intelligence newsletter. [supsystic-tables id=11 ] Like This & Want More? Sign up to get […]

FDA warned 9 firms that operate a total of 53 websites to stop illegally marketing unapproved versions of opioid medications. FDA reminds the public that no one is authorized to sell or distribute opioids via the internet, with or without a prescription. A total of 17 warning letters were posted this week. We cover 3 […]